Analyst Ratings for Myriad Genetics (MYGN)
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $10.00 (Craig-Hallum)
- Lowest: $2.00 (Piper Sandler)
- Average: $4.36
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$4.36 (+37%)
* Over Last 12-Mos
Rating Score: 2 / 10
Percentile Rank: 15%
Avg. $ Target:
$4.36 (+37%)
* Over Last 12-Mos
Rating Score: 2 / 10
Percentile Rank: 15%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Piper Sandler | Dave Westenberg | Downgrade | Underweight (Neutral) |
2.00 (5.45) |
3.16 (3.18) |
0.63% | Details |
| 5/21/2025 | Scotiabank | Sung Ji Nam | Downgrade | Sector Perform (Sector Outperform) |
6.00 (20.00) |
4.43 (3.18) |
-28.22% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
